simendan has been researched along with Chronic Disease in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.23) | 18.2507 |
| 2000's | 14 (45.16) | 29.6817 |
| 2010's | 15 (48.39) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Mamalyga, LM; Mamalyga, ML | 1 |
| Alaa, M; Leite, S; Leite-Moreira, AF; Lopes, L; Lourenço, AP; Oliveira-Pinto, J; Tavares-Silva, M | 1 |
| Altenberger, J; Gustafsson, F; Harjola, VP; Karason, K; Kindgen-Milles, D; Kivikko, M; Malfatto, G; Papp, Z; Parissis, J; Pollesello, P; Pölzl, G; Tschöpe, C | 1 |
| Bouchez, S; Fedele, F; Giannakoulas, G; Gustafsson, F; Harjola, VP; Karason, K; Kivikko, M; Oliva, F; Papp, Z; Parissis, J; Pollesello, P; Pölzl, G; Tschöpe, C; von Lewinski, D | 1 |
| de Lurdes, CM; Di Prima, AL; Greco, T; Landoni, G; Mucchetti, M; Pasin, L; Scandroglio, M; Silvetti, S; Zangrillo, A | 1 |
| Altenberger, J; Ben-Gal, T; Böhmer, A; Comin-Colet, J; Dickstein, K; Edes, I; Fedele, F; Fonseca, C; García-González, MJ; Giannakoulas, G; Iakobishvili, Z; Jääskeläinen, P; Karavidas, A; Kettner, J; Kivikko, M; Lund, LH; Matskeplishvili, ST; Metra, M; Morandi, F; Nieminen, MS; Oliva, F; Parissis, J; Parkhomenko, A; Pollesello, P; Pölzl, G; Schwinger, RH; Segovia, J; Seidel, M; Vrtovec, B; Wikström, G | 1 |
| Li, JX; Niu, LL; Yi, GY; Zhang, CY; Zhang, J | 1 |
| Anastasiou-Nana, M; Dimopoulos, S; Gerovasili, V; Kaldara, E; Kourtidou, S; Nanas, J; Nanas, S; Pierrakos, C; Roussos, C; Sarafoglou, S; Venetsanakos, J | 1 |
| Harjola, VP; Jurkko, R; Nieminen, MS; Oikarinen, L; Puttonen, J; Sarapohja, T; Sundberg, S; Toivonen, L | 1 |
| Belenkov, Y; Cleland, JG; Eha, J; Kivikko, M; Nieminen, MS; Põder, P; Sarapohja, T | 1 |
| Bistola, V; Farmakis, D; Filippatos, G; Iliodromitis, EK; Kremastinos, DT; Paraskevaidis, IA; Parissis, JT | 1 |
| Bonios, M; Drakos, SG; Kaldara, E; Kanakakis, JV; Katsaros, F; Nanas, JN; Nanas, S; Pantsios, C | 1 |
| Branzi, G; Ciambellotti, F; Facchini, M; Giglio, A; Malfatto, G; Parati, G; Revera, M; Rosa, FD; Villani, A | 1 |
| Batur, MK; Kurt, IH; Yavuzer, K | 1 |
| Anastasiou-Nana, M; Bistola, V; Ikonomidis, I; Papadopoulos, C; Paraskevaidis, IA; Parissis, J; Stassinos, V | 1 |
| Bongo, AS; Lazzero, M; Lupi, A; Rognoni, A; Rognoni, G | 1 |
| Harjola, VP; Jalanko, M; Kivikko, M; Laine, M; Nieminen, MS | 1 |
| Bocchi, EA; Carvalho, VO; Cruz, F; Guimarães, GV; Issa, VS; Moura, LZ | 1 |
| Amir, O; Zafrir, B | 1 |
| Branzi, G; Della Rosa, F; Facchini, M; Malfatto, G; Parati, G; Rella, V; Villani, A | 1 |
| Boldt, J; Kirchner, J; Lehmann, A | 1 |
| McBride, BF; White, CM | 1 |
| Anker, SD; Diller, GP; von Haehling, S | 1 |
| Alexopoulos, GP; Anastasiou-Nana, MI; Kanakakis, J; Nanas, JN; Nanas, SN; Ntalianis, A; Papazoglou, P; Terrovitis, JV; Tsagalou, EP; Tsolakis, E | 1 |
| Csapó, K; Edes, I; Haikala, H; Papp, Z; Pollesello, P | 1 |
| McLachlan, CS; Mossop, P | 1 |
| Adamopoulos, S; Farmakis, D; Filippatos, GS; Gheorghiade, M; Iliodromitis, EK; Karatzas, D; Kremastinos, DT; Paraskevaidis, I; Parissis, JT; Tsiapras, D | 1 |
| Arapi, S; Bistola, V; Farmakis, D; Filippatos, G; Karavidas, A; Korres, D; Kremastinos, DT; Matsakas, E; Paraskevaidis, IA; Parissis, JT | 1 |
| Kajimoto, K; Kawana, M; Watanabe, H | 1 |
| Afanas'ev, SA; Karpov, RS; Timofeev, VIu | 1 |
| Antila, S; Eha, J; Kivikko, M; Lehtonen, L; Pentikäinen, PJ | 1 |
10 review(s) available for simendan and Chronic Disease
| Article | Year |
|---|---|
Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications.
Topics: Acute Disease; Cardiotonic Agents; Chronic Disease; Clinical Decision-Making; Congresses as Topic; Databases, Factual; Heart Failure; Humans; Myocardial Contraction; Patient Selection; Recovery of Function; Risk Factors; Simendan; Treatment Outcome; Vasodilation; Vasodilator Agents | 2018 |
Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application.
Topics: Acute Disease; Cardiotonic Agents; Chronic Disease; Congresses as Topic; Evidence-Based Medicine; Heart Failure; Humans; Kidney; Myocardial Contraction; Recovery of Function; Simendan; Time Factors; Treatment Outcome; Vasodilator Agents | 2018 |
Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials.
Topics: Administration, Intravenous; Adult; Cardiotonic Agents; Chronic Disease; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Survival Rate; Time Factors | 2014 |
Repetitive infusion of levosimendan in patients with chronic heart failure: a meta-analysis.
Topics: Chronic Disease; Clinical Trials as Topic; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Stroke Volume | 2015 |
Levosimendan: from basic science to clinical trials.
Topics: Acute Disease; Animals; Calcium Channels; Cardiovascular Agents; Chronic Disease; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Myocardium; Oxygen Consumption; Potassium Channels; Pyridazines; Simendan; Translational Research, Biomedical; Treatment Outcome; Ventricular Function | 2011 |
Beta blocker therapy, decompensated heart failure, and inotropic interactions: current perspectives.
Topics: Acute Disease; Adrenergic beta-Antagonists; Cardiotonic Agents; Chronic Disease; Dobutamine; Drug Interactions; Drug Therapy, Combination; Heart Failure; Hospitalization; Humans; Hydrazones; Phosphodiesterase Inhibitors; Practice Guidelines as Topic; Pyridazines; Simendan | 2012 |
The role of Ca++-sensitizers for the treatment of heart failure.
Topics: Calcium; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Dobutamine; Heart Failure; Hemodynamics; Humans; Hydrazones; Myocardial Ischemia; Pyridazines; Simendan | 2003 |
Levosimendan: implications for clinicians.
Topics: Calcium; Cardiotonic Agents; Chronic Disease; Controlled Clinical Trials as Topic; Drug Interactions; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2003 |
Pharmacological mechanisms contributing to the clinical efficacy of levosimendan.
Topics: Animals; Chronic Disease; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Treatment Outcome | 2005 |
[Combination therapy with PDE III inhibitor for heart failure].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Chronic Disease; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 3; Dobutamine; Drug Therapy, Combination; Heart Failure; Humans; Hydrazones; Milrinone; Phosphodiesterase Inhibitors; Pyridazines; Simendan | 2007 |
11 trial(s) available for simendan and Chronic Disease
| Article | Year |
|---|---|
The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure.
Topics: Acetamides; Administration, Oral; Aged; Area Under Curve; Cardiotonic Agents; Chronic Disease; Digoxin; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Magnetocardiography; Male; Middle Aged; Pyridazines; Simendan | 2008 |
Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
Topics: Aged; Biomarkers; Cardiotonic Agents; Chronic Disease; Disease Progression; Double-Blind Method; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Psychometrics; Pyridazines; Quality of Life; Severity of Illness Index; Simendan; Surveys and Questionnaires | 2008 |
Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure.
Topics: Acute Disease; Aged; Biomarkers; Cardiotonic Agents; Chronic Disease; Disease-Free Survival; Female; Follow-Up Studies; Heart Failure; Heart Function Tests; Humans; Hydrazones; Kaplan-Meier Estimate; Male; Middle Aged; Natriuretic Peptide, Brain; Patient Readmission; Predictive Value of Tests; Pyridazines; Sensitivity and Specificity; Simendan; Ultrasonography | 2010 |
Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure.
Topics: Aged; Cardiography, Impedance; Cardiotonic Agents; Chronic Disease; Diastole; Echocardiography, Doppler; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Italy; Male; Middle Aged; Mitral Valve Insufficiency; Natriuretic Peptide, Brain; Pilot Projects; Pyridazines; Severity of Illness Index; Simendan; Stroke Volume; Systole; Time Factors; Treatment Outcome; Vasodilator Agents; Ventricular Function, Left | 2010 |
Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cardiotonic Agents; Chronic Disease; Down-Regulation; Female; Heart Failure; Humans; Hydrazones; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Severity of Illness Index; Simendan; Stroke Volume; Time Factors; Treatment Outcome; Turkey | 2010 |
Oral levosimendan improves filling pressure and systolic function during long-term treatment.
Topics: Administration, Oral; Aged; Blood Pressure; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Hydrazones; Male; Middle Aged; Prospective Studies; Pyridazines; Severity of Illness Index; Simendan; Systole; Time Factors; Treatment Outcome; Vasodilator Agents | 2011 |
Effects of the recombinant form of the natural human B-type natriuretic peptide and levosimendan on pulmonary hyperventilation and chemosensivity in heart failure.
Topics: Adult; Brazil; Cardiovascular Agents; Chemoreceptor Cells; Chronic Disease; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Hypercapnia; Hyperventilation; Hypoxia; Infusions, Intravenous; Lung; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyridazines; Recombinant Proteins; Respiratory Rate; Simendan; Time Factors; Treatment Outcome | 2013 |
Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance, and one-year survival.
Topics: Aged; Calcium; Chronic Disease; Data Interpretation, Statistical; Diuretics; Drug Administration Schedule; Female; Furosemide; Heart Failure; Heart Function Tests; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Mortality; Natriuretic Peptide, Brain; Pyridazines; Severity of Illness Index; Simendan; Treatment Outcome; Ventricular Function | 2012 |
Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Topics: Aged; Apoptosis; Cardiotonic Agents; Chronic Disease; Dobutamine; Echocardiography; Fas Ligand Protein; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Interleukin-6; Male; Membrane Glycoproteins; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Pulmonary Wedge Pressure; Pyridazines; Simendan; Stroke Volume; Treatment Outcome; Tumor Necrosis Factor-alpha; Tumor Necrosis Factors | 2006 |
Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure.
Topics: Aged; Chronic Disease; Endothelium, Vascular; Female; Heart Failure; Humans; Hydrazones; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Middle Aged; Natriuretic Peptide, Brain; Nitroglycerin; Pyridazines; Severity of Illness Index; Simendan; Solubility; Stroke Volume; Vascular Cell Adhesion Molecule-1; Vasodilation; Vasodilator Agents | 2008 |
Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
Topics: Aged; Analysis of Variance; Blood Pressure; Body Weight; Calcium Channel Blockers; Cardiotonic Agents; Chronic Disease; Electrocardiography; Erythrocyte Indices; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Simendan | 2002 |
10 other study(ies) available for simendan and Chronic Disease
| Article | Year |
|---|---|
Experimental Study of Heart Functionality during Treatment of Chronic Heart Failure in Rats of Different Age Groups with Levosimendan (Experimental Study).
Topics: Animals; Chronic Disease; Disease Models, Animal; Doxorubicin; Heart; Heart Failure; Heart Function Tests; Male; Myocardium; Rats; Rats, Wistar; Simendan | 2020 |
Dose-Response Head-to-Head Comparison of Inodilators Dobutamine, Milrinone, and Levosimendan in Chronic Experimental Pulmonary Hypertension.
Topics: Animals; Calcium; Chronic Disease; Dobutamine; Dose-Response Relationship, Drug; Hemodynamics; Hydrazones; Hypertension, Pulmonary; Male; Milrinone; Pyridazines; Rats; Rats, Wistar; Simendan | 2017 |
Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus.
Topics: Chronic Disease; Heart Failure; Humans; Hydrazones; Practice Guidelines as Topic; Pyridazines; Severity of Illness Index; Simendan; Vasodilator Agents | 2014 |
Inotropic agents improve the peripheral microcirculation of patients with end-stage chronic heart failure.
Topics: Adrenergic beta-Agonists; Brachial Artery; Cardiotonic Agents; Case-Control Studies; Chronic Disease; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Male; Microcirculation; Middle Aged; Muscle, Skeletal; Myocardial Reperfusion; Oxygen Consumption; Prognosis; Prospective Studies; Pyridazines; Simendan; Spectroscopy, Near-Infrared; Vasodilator Agents | 2008 |
Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Cardiotonic Agents; Chronic Disease; Dobutamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Pyridazines; Simendan; Survival Rate; Treatment Outcome | 2009 |
Dobutamine-induced changes of left atrial two-dimensional deformation predict clinical and neurohumoral improvement after levosimendan treatment in patients with acutely decompensated chronic heart failure.
Topics: Aged; Atrial Function, Left; Biomarkers; Chronic Disease; Dobutamine; Echocardiography; Echocardiography, Stress; Female; Forecasting; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Pyridazines; Simendan; Treatment Outcome | 2012 |
Impact of levosimendan treatment on chronic heart failure.
Topics: Anti-Inflammatory Agents; Chronic Disease; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2004 |
Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone.
Topics: Adult; Aged; Cardiotonic Agents; Chronic Disease; Dobutamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Multivariate Analysis; Pyridazines; Radionuclide Ventriculography; Risk; Simendan; Survival Rate | 2005 |
Levosimendan and plasma BNP levels: do inflammatory cytokines regulate BNP in chronic decompensated heart failure?
Topics: Alprostadil; Biomarkers; Cardiotonic Agents; Chronic Disease; Cytokines; Dose-Response Relationship, Drug; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Pyridazines; Simendan; Stroke Volume; Vasodilator Agents | 2006 |
[Troponin component of the cardiotropic effect of levosimendan on the isolated myocardium from patients with chronic coronary insufficiency].
Topics: Adrenergic beta-Agonists; Cardiotonic Agents; Chronic Disease; Epinephrine; Heart; Humans; Hydrazones; In Vitro Techniques; Middle Aged; Myocardial Contraction; Myocardial Ischemia; Pyridazines; Simendan; Stimulation, Chemical | 1999 |